Physician profile
Avnee Shah
NPI 1750600656
$10,777.59
in general payments reported to CMS, 2019-2025
36 companies · $2,458 in 2025
The $2,458 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $540 · 2021: $747 · 2022: $1,843 · 2023: $2,841 · 2024: $1,700 · 2025: $2,458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,819 · Consulting Fee: $1,100 · Education: $80.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,819.16 |
| Consulting Fee | $1,100.00 |
| Education | $80.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,695.35 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Leo Pharma INC. | $1,909.59 | 2023-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $921.09 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Pfizer INC. | $775.34 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $499.83 | 2021-2025 | Blu-U, Odomzo, Ilumya |
| Incyte Corporation | $476.85 | 2021-2024 | Opzelura |
| Arcutis Biotherapeutics, INC. | $462.98 | 2023-2025 | Zoryve |
| Genzyme Corporation | $454.87 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $358.13 | 2019-2025 | Dupixent, Libtayo |
| Amgen INC. | $356.55 | 2020-2025 | Otezla, Otezla |
| Lilly USA, LLC | $347.10 | 2022-2025 | Taltz, Olumiant, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $333.75 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $157.53 | 2024-2025 | |
| Dermavant Sciences, INC. | $121.59 | 2022-2024 | Vtama |
| Vyne Pharmaceuticals INC. | $110.09 | 2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $100.92 | 2024-2025 | Tremfya |
| Journey Medical Corporation | $88.80 | 2019-2025 | |
| Ucb, INC. | $85.09 | 2019-2024 | Bimzelx, Cimzia |
| Botanix Sb INC | $69.67 | 2025 | Sofdra |
| Almirall LLC | $61.15 | 2019-2024 | Klisyri |
| Epi Health, LLC | $54.42 | 2020-2022 | |
| Mayne Pharma Commercial LLC | $52.75 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $44.53 | 2021-2022 | |
| Kyowa Kirin, INC. | $43.27 | 2021-2024 | Poteligeo |
| Genentech USA, INC. | $29.89 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.09 | 2022-2023 | Spevigo |
| Optinose US, INC. | $16.91 | 2024 | |
| Blueprint Medicines Corporation | $16.35 | 2023 | |
| Merck Sharp & Dohme LLC | $14.45 | 2019 | |
| Fidia Pharma USA INC. | $14.36 | 2024 | |
| Strata Skin Sciences, INC. | $13.96 | 2025 | Xtrac |
| Nabriva Therapeutics, Plc | $13.75 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.52 | 2024 | Cabtreo, Arazlo, Jublia |
| Sebela Pharmaceuticals INC. | $12.68 | 2019 | |
| Encore Dermatology INC. | $11.83 | 2020 | |
| Organon LLC | $9.56 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avnee Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.